[Guideline development for MRD diagnostics in AML as a blueprint for solid tumors]
{{output}}
Background: In acute myeloid leukemia (AML), the monitoring of measurable residual disease (MRD) has evolved over the past two decades from predominantly prognostic supplementary information to a central tool for risk stratificat... ...
